Biomaterial Database

Methods for evaluating treatment in Parkinson's disease. 1983

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Objective measurements of movement time, reaction time, and gait were compared with a clinical rating performed at the same times on several occasions in 10 patients with Parkinson's disease (PD). Positive correlations between objective measures and clinical evaluation were demonstrated. Movement time was the single most useful index of motor deficit, but no objective tests were more sensitive than clinical evaluations in the detection of motor disorder. It is concluded that there is at present no effective substitute for clinical procedures, although the convenience and future potential of objective measurement justify the further development of such systems for use in the experimental study of PD.

UI	MeSH Term	Description	Entries
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009069	Movement Disorders	Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	Dyskinesia Syndromes,Etat Marbre,Status Marmoratus,Movement Disorder Syndromes,Dyskinesia Syndrome,Movement Disorder,Movement Disorder Syndrome
D010300	Parkinson Disease	A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011930	Reaction Time	The time from the onset of a stimulus until a response is observed.	Response Latency,Response Speed,Response Time,Latency, Response,Reaction Times,Response Latencies,Response Times,Speed, Response,Speeds, Response
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D013997	Time Factors	Elements of limited time intervals, contributing to particular results or situations.	Time Series,Factor, Time,Time Factor

Related Publications

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

[Methods for evaluating of olfactory function in patients with Parkinson's disease].

January 2015, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.

July 2019, Expert opinion on pharmacotherapy,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Evaluating treatment methods for depressive disorders.

May 1968, The American journal of psychiatry,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Methods for evaluating treatment of uroliths.

January 1999, The Veterinary clinics of North America. Small animal practice,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Evaluating methods of oversampling and averaging resting-state electroencephalography data in classifying Parkinson's disease.

July 2023, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Parkinson's Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson's Disease: A Systematic Review.

August 2020, Brain sciences,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

Methods for assessing mortality in Parkinson's disease surveys.

June 2012, Movement disorders : official journal of the Movement Disorder Society,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

[Surgical treatment of Parkinson's disease: evaluation of present methods].

July 1954, Prensa medica argentina,

C D Ward, and J N Sanes, and J M Dambrosia, and D B Calne

A Psychometric Tool for Evaluating Executive Functions in Parkinson's Disease.

February 2022, Journal of clinical medicine,